Medtronic To Pay J&J $270M Over Stent Patent Fees
Law360, New York (May 11, 2009) -- Medtronic Inc. has agreed to fork over $270 million in a bid to bury the hatchet with Johnson & Johnson in a long-running dispute over royalties concerning three stent patents used in heart surgeries.
Minneapolis-based Medtronic said Friday the deal would end all current and potential royalty disputes between it and J&J under a 1997 settlement and license agreement relating to three patents known...
************************************...